ImmuNext develops compounds on the cutting edge of immunotherapy for cancer and autoimmune diseases. Novel immunomodulators have been partnered with Janssen, Roche and Sanofi. ImmuNext currently has a clinical stage program with VISTA, a checkpoint regulator, and pre-clinical programs focused on the development of antibodies that target novel immuno-metabolic proteins.
Sponsored Ad
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.